Evidence map›Paper›PMID 37691494›Full record

ArticleEMBO reports2023

Defects in microvillus crosslinking sensitize to colitis and inflammatory bowel disease.

Bernadette Mödl, Monira Awad, Daniela Zwolanek, Irene Scharf, Katharina Schwertner, Danijela Milovanovic, Doris Moser, Katy Schmidt, Petra Pjevac, Bela Hausmann and 9 more

Open access · hybridAbstract read
In one paragraph

Article in EMBO reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Impact of oralmSystems · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Bernadette Mödl *Center for Cancer Research, Medical University of Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.
Monira Awad *Center for Cancer Research, Medical University of Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.
Daniela ZwolanekCenter for Cancer Research, Medical University of Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.ORCID 0000-0001-5250-396X
Irene ScharfCenter for Cancer Research, Medical University of Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.
Katharina SchwertnerCenter for Cancer Research, Medical University of Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.ORCID 0000-0002-5916-1058
Danijela MilovanovicDepartment of Experimental and Translational Pathology, Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
Doris MoserDepartment of Cranio-Maxillofacial and Oral Surgery, Medical University of Vienna, Vienna, Austria.
Katy SchmidtCell Imaging & Ultrastructure Research, University of Vienna, Vienna, Austria.
Petra PjevacJoint Microbiome Facility of the Medical University of Vienna and the University of Vienna, Vienna, Austria.
Bela HausmannJoint Microbiome Facility of the Medical University of Vienna and the University of Vienna, Vienna, Austria.
Dana KraußCenter for Cancer Research, Medical University of Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.ORCID 0000-0002-7310-4340
Thomas MohrCenter for Cancer Research, Medical University of Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.
Jasmin SvinkaCenter for Cancer Research, Medical University of Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.
Lukas KennerDepartment of Experimental and Translational Pathology, Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-2184-1338
Emilio CasanovaCenter of Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.ORCID 0000-0001-7992-5361
Gerald TimelthalerCenter for Cancer Research, Medical University of Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.ORCID 0000-0002-0260-089X
Maria SibiliaCenter for Cancer Research, Medical University of Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.ORCID 0000-0001-6129-5613
Sigurd Krieger *Department of Experimental and Translational Pathology, Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
Robert Eferl *Center for Cancer Research, Medical University of Vienna & Comprehensive Cancer Center (CCC), Vienna, Austria.ORCID 0000-0002-6074-7144
Comprehensive Cancer Center Vienna · ATMedical University of Vienna · ATUniversity of Vienna · ATUniversity of Veterinary Medicine Vienna · AT

Funding

Austrian Science Fund (FWF) DOC 59-833Austrian Science Fund (FWF) P32900-BAustrian Science Fund (FWF) P33430Austrian Science Fund (FWF) P35069-BAustrian Science Fund FWF P 32900EC | European Research Council (ERC) ERC-2015-AdG TNT-Tumors 694883EC | Horizon 2020 Framework Programme (H2020) 766214
6 · The paper itself

Abstract

Intestinal epithelial cells are covered by the brush border, which consists of densely packed microvilli. The Intermicrovillar Adhesion Complex (IMAC) links the microvilli and is required for proper brush border organization. Whether microvillus crosslinking is involved in the intestinal barrier function or colitis is currently unknown. We investigate the role of microvillus crosslinking in colitis in mice with deletion of the IMAC component CDHR5. Electron microscopy shows pronounced brush border defects in CDHR5-deficient mice. The defects result in severe mucosal damage after exposure to the colitis-inducing agent DSS. DSS increases the permeability of the mucus layer and brings bacteria in direct contact with the disorganized brush border of CDHR5-deficient mice. This correlates with bacterial invasion into the epithelial cell layer which precedes epithelial apoptosis and inflammation. Single-cell RNA sequencing data of patients with ulcerative colitis reveals downregulation of CDHR5 in enterocytes of diseased areas. Our results provide experimental evidence that a combination of microvillus crosslinking defects with increased permeability of the mucus layer sensitizes to inflammatory bowel disease.

Indexed as

Inflammatory Bowel DiseasesIntestinal MucosaMicrovilliAnimalsCadherinsColitisDextran SulfateDisease Models, AnimalEnterocytesEpithelial CellsHumansMiceMice, Inbred C57BLMice, KnockoutPermeabilityCadherinsDextran Sulfatebrush borderCDHR5colitismicrovilliMUCDHL

Identifiers

PMID37691494
PMCPMC10561180
OpenAlexW4386592499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.